Cargando…

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus

AIM: To evaluate the effect of final HbA(1c) levels on the incidences of hypoglycaemia in participants with type 1 diabetes treated with inhaled Technosphere(®) Insulin or subcutaneous insulin aspart, reported in alignment with the International Hypoglycaemia Study Group recommendations. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., Grant, M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216876/ https://www.ncbi.nlm.nih.gov/pubmed/31811662 http://dx.doi.org/10.1111/dme.14202

Ejemplares similares

Comprehensive Pulmonary Safety Review of Inhaled Technosphere(®) Insulin in Patients with Diabetes Mellitus
por: McGill, Janet B., et al.
Publicado: (2020)

Place of technosphere inhaled insulin in treatment of diabetes
por: Mikhail, Nasser
Publicado: (2016)

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021)

A Population Dose–Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
por: Rüppel, D, et al.
Publicado: (2017)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
por: Akturk, Halis Kaan, et al.
Publicado: (2018)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin
por: Bell, David S. H., et al.
Publicado: (2020)

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2023)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator
por: Visentin, Roberto, et al.
Publicado: (2016)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Insulin Hypoglycæmia
Publicado: (1948)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
por: Franek, E., et al.
Publicado: (2015)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
por: Glastras, Sarah J., et al.
Publicado: (2020)

Insulin aspart in patients with gestational diabetes mellitus and pregestational diabetes mellitus
por: Deepaklal, M. C., et al.
Publicado: (2015)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Hypoglycaemia in adults with insulin‐treated diabetes in the UK: self‐reported frequency and effects
por: Frier, B. M., et al.
Publicado: (2015)

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
por: Frier, Brian M., et al.
Publicado: (2019)

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
por: Leelarathna, Lalantha, et al.
Publicado: (2018)

Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus
por: Pettitt, D. J., et al.
Publicado: (2007)

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting
por: Russell‐Jones, David, et al.
Publicado: (2017)

Infusion of N‐acetyl cysteine during hypoglycaemia in humans does not preserve the counterregulatory response to subsequent hypoglycaemia
por: Moheet, Amir, et al.
Publicado: (2020)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study
por: Home, Philip, et al.
Publicado: (2018)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
por: Hermansen, Kjeld, et al.
Publicado: (2015)

Effects of insulin aspart and metformin on gestational diabetes mellitus and inflammatory markers
por: Wang, Yan, et al.
Publicado: (2023)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bnok8lqs7br84hlc5agrka5h0m